This site is intended for U.S. healthcare professionals.
CAPiTA: Community-Acquired Pneumonia Immunization Trial in Adults
Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) was evaluated in a landmark trial of nearly 85,000 participants1-3
|Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) study description||Study end points|
|Adults age 65 or older||Primary|
|Adults were excluded if they:||Secondary|
~85,000 adults age 65 or older participated in CAPiTA1,2
(95.2% CI, 21.8-62.5) of a first episode of either vaccine-type nonbacteremic/noninvasive or vaccine-type bacteremic/invasive pneumococcal CAP (Number of episodes: Prevnar 13 n=49; placebo n=90)
(95.2% CI, 14.2-65.3) of a first episode of vaccine-type nonbacteremic/noninvasive pneumococcal CAP (Number of episodes: Prevnar 13 n=33; placebo n=60)
(95% CI, 41.4-90.8) of a first episode of vaccine-type IPD (Number of episodes: Prevnar 13 n=7; placebo n=28)
|Local adverse events (%)||PCV13
|Limitation of arm movement (any)||14.1†||3.2|
|Incidence of fever (%)||PCV13
|Systemic adverse events (%)||PCV13
|New muscle pain‡||18.4†||8.4|
|Aggravated muscle pain‡||9.1†||4.4|
|New joint pain‡||7.4||5.4|
|Aggravated joint pain‡||5.2||4.2|
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2023 Pfizer Inc. All rights reserved.